Propionic Acidemia Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | HemoShear Therapeutics, BridgeBio, Agios Pharmaceuticals, VectivBio, Moderna

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Propionic Acidemia pipeline constitutes 5+ key companies continuously working towards developing 5+ Propionic Acidemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Propionic Acidemia Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Propionic Acidemia Market.

The Propionic Acidemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Propionic Acidemia Pipeline Report: https://www.delveinsight.com/sample-request/propionic-acidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Propionic Acidemia treatment therapies with a considerable amount of success over the years.
• Propionic Acidemia companies working in the treatment market are HemoShear Therapeutics, BridgeBio, Agios Pharmaceuticals, VectivBio, Moderna, CoA Therapeutics, Inc., and others, are developing therapies for the Propionic Acidemia treatment
• Emerging Propionic Acidemia therapies in the different phases of clinical trials are- VB-1197, BCAT2 inhibitors, BBP-671, HST 5040, and others are expected to have a significant impact on the Propionic Acidemia market in the coming years.
• In July 2022, HemoShear Therapeutics initiated a Phase II open-label, dose escalation study ofHST5040 in subjects with Propionic or Methylmalonic acidemia followed by a randomized, double-blind,placebo-controlled, 2-period crossover study and an open-label, long-term extension study. This is aninterventional study to assess the safety, PK, and efficacy of HST5040 in 12 subjects - 6 with MethylmalonicAcidemia (MMA) and 6 with Propionic Acidemia (PA).
• In December 2020, HemoShear Therapeutics announced that the US Food and Drug Administration (FDA)granted Orphan Drug Designations to HemoShear's HST5040 oral small molecule for treatment ofmethylmalonic acidemia (MMA) and propionic acidemia (PA).

Propionic Acidemia Overview
Propionic acidemia is an uncommon metabolic condition that affects anywhere between 1/20,000 and 1/250,000 people worldwide. Propionyl-CoA carboxylase deficiency, an enzyme involved in the breakdown (catabolism) of the chemical "building blocks" (amino acids) of proteins, is one of its defining characteristics.

Get a Free Sample PDF Report to know more about Propionic Acidemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/propionic-acidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Propionic Acidemia Drugs Under Different Phases of Clinical Development Include:
• VB-1197: VectivBio
• BCAT2 inhibitors: Agios Pharmaceuticals
• BBP-671: BridgeBio
• HST 5040: HemoShear Therapeutics
• mRNA-3927: Moderna

Propionic Acidemia Route of Administration
Propionic Acidemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Propionic Acidemia Molecule Type
Propionic Acidemia Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Propionic Acidemia Pipeline Therapeutics Assessment
• Propionic Acidemia Assessment by Product Type
• Propionic Acidemia By Stage and Product Type
• Propionic Acidemia Assessment by Route of Administration
• Propionic Acidemia By Stage and Route of Administration
• Propionic Acidemia Assessment by Molecule Type
• Propionic Acidemia by Stage and Molecule Type

DelveInsight's Propionic Acidemia Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Propionic Acidemia product details are provided in the report. Download the Propionic Acidemia pipeline report to learn more about the emerging Propionic Acidemia therapies at:
https://www.delveinsight.com/sample-request/propionic-acidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Propionic Acidemia Pipeline Analysis:
The Propionic Acidemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Propionic Acidemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Propionic Acidemia Treatment.
• Propionic Acidemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Propionic Acidemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Propionic Acidemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Propionic Acidemia drugs and therapies-
https://www.delveinsight.com/sample-request/propionic-acidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Propionic Acidemia Pipeline Market Drivers
• Increasing awareness regarding propionic academia, increasing geriatric population, improvement in treatment and R&D are some of the important factors that are fueling the Propionic Acidemia Market.

Propionic Acidemia Pipeline Market Barriers
• However, increasing awareness regarding the propionic academia, increasing geriatric population, improvement in treatment and R&D and other factors are creating obstacles in the Propionic Acidemia Market growth.

Scope of Propionic Acidemia Pipeline Drug Insight
• Coverage: Global
• Key Propionic Acidemia Companies: HemoShear Therapeutics, BridgeBio, Agios Pharmaceuticals, VectivBio, Moderna, CoA Therapeutics, Inc., and others
• Key Propionic Acidemia Therapies: VB-1197, BCAT2 inhibitors, BBP-671, HST 5040, and others
• Propionic Acidemia Therapeutic Assessment: Propionic Acidemia current marketed and Propionic Acidemia emerging therapies
• Propionic Acidemia Market Dynamics: Propionic Acidemia market drivers and Propionic Acidemia market barriers

Request for Sample PDF Report for Propionic Acidemia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/propionic-acidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Propionic Acidemia Report Introduction
2. Propionic Acidemia Executive Summary
3. Propionic Acidemia Overview
4. Propionic Acidemia- Analytical Perspective In-depth Commercial Assessment
5. Propionic Acidemia Pipeline Therapeutics
6. Propionic Acidemia Late Stage Products (Phase II/III)
7. Propionic Acidemia Mid Stage Products (Phase II)
8. Propionic Acidemia Early Stage Products (Phase I)
9. Propionic Acidemia Preclinical Stage Products
10. Propionic Acidemia Therapeutics Assessment
11. Propionic Acidemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Propionic Acidemia Key Companies
14. Propionic Acidemia Key Products
15. Propionic Acidemia Unmet Needs
16 . Propionic Acidemia Market Drivers and Barriers
17. Propionic Acidemia Future Perspectives and Conclusion
18. Propionic Acidemia Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Propionic Acidemia Market https://www.delveinsight.com/report-store/propionic-acidemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Propionic Acidemia-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.